Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 2

Abstract

The online version of this article (doi:10.1208/s12248-013-9463-9) contains supplementary material, which is available to authorized users.

Authors and Affiliations

Rui Zhu, Yanan Zheng, Wendy S. Putnam, Jennifer Visich, Mark D. Eisner, John G. Matthews, Karin E. Rosen, David Z. D’Argenio

Keywords

Related Articles

Evaluation of sucrose esters as alternative surfactants in microencapsulation of proteins by the solvent evaporation method

Sucrose esters (SE) are surfactants with potential pharmaceutical applications because of their low toxicity, biocompatibility, and excellent biodegradability. The objective of the study was to investigate SE as alternat...

Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients

The online version of this article (doi:10.1208/s12248-014-9626-3) contains supplementary material, which is available to authorized users.

Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment

The administration of human biotherapeutics is often associated with a higher incidence of immunogenicity in preclinical species. The presence of anti-drug antibodies (ADAs) in the test samples can affect the accurate me...

Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?

CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was teste...

Download PDF file
  • EP ID EP681106
  • DOI  10.1208/s12248-013-9463-9
  • Views 64
  • Downloads 0

How To Cite

Rui Zhu, Yanan Zheng, Wendy S. Putnam, Jennifer Visich, Mark D. Eisner, John G. Matthews, Karin E. Rosen, David Z. D’Argenio (2013). Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy. The AAPS Journal, 15(2), -. https://europub.co.uk/articles/-A-681106